

ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Diaceutics

DXRX 110p ▼ -1.5 -1.3%Speculative, Small Cap, **Falling Star**

Market Cap

£93.7m

Quality

66

Enterprise Value

£68.6m

Value

21

Revenue

£12.7m

Momentum

16

Market Cap Rank

1053rd / 1781

StockRank™

25

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All

**Momentum**

Relative Strength (%)

1m +0.8% ●

3m -13.1% ●

1yr -22.1% ●

Volume Change (%)

10d v 3m -68.3% ●

Price vs... (%)

52w High -26.6% ●

50d MA -1.52% ●

200d MA -10.1% ●

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (f) 46.2

PEG Ratio (f) 0.72

EPS Growth (f) 179.8 %

Dividend Yield (f) n/a %

Valuation (ttm)

Price to Book Value 2.33

Price to Tang. Book 3.04

Price to Free Cashflow n/a

Price to Sales 7.38

EV to EBITDA 454.3

Quality

vs. industry vs. market

Return on Capital -1.62 %

Return on Equity 0.87 %

Operating Margin -5.18 %

Health Trend Piotroski F-Score

4

**Bankruptcy Risk** Altman Z2-Score

34.8

**Earnings Manipulation Risk**

Low

Magic Formula Score

1639 40% D+

**Other Ratios**

Leverage (ttm)		total	-intang	+pension
Gross Gearing	%	0.29	0.38	0.29
Net Gearing	%	-62.5	-81.4	-62.5
Cash / Assets	%	58.0		58.0

Liquidity (ttm)		Efficiency (ttm)	
Curr. Ratio	11.5 ●	Asset Turnover	0.29
Quick Ratio	11.5 ●	Rec's Turnover	2.66
Interest Cov.	-27.4 ●	Stock Turnover	n/a

Recent History

vs. industry vs. market

Latest interim period (ended 31st Dec '20) vs. prior year

Sales Growth -18.5 %

EPS Growth n/a %

3yr Compound Annual Growth Rate

Sales Growth 19.9 %

EPS Growth -8.05 %

DPS Growth n/a %

Margin of Safety (beta)

Broker Target	
Relative to Sector	-35%
Graham Formula	-8%
Stability Value (EPV)	-66%


Screens Passed

DXRX doesn't qualify for any screens.

Find out why: [View Checklists](#)**Financial Summary**

Balance Sheet · Income Statement · Cashflow


Year End 31st Dec		2015	2016	2017	2018	2019	2020	2021E	2022E	CAGR / Avg
Revenue	£m	0.000	4.59	7.37	10.4	13.4	12.7	13.6	16.5	+29.0%
Operating Profit	£m	0.000	0.88	0.90	1.20	0.74	-0.66			
Net Profit	£m	0.000	0.75	0.66	0.63	0.40	0.26	0.80	2.50	-23.0%
EPS Reported	p	0.000	1.07	0.95	0.91	0.62	0.34			-25.1%
EPS Normalised	p	0.000	1.07	0.95	1.12	2.30	0.74	0.91	3.01	-8.9%
EPS Growth	%			-11.3	+17.6	+105.2	-67.8	+22.8	+230.8	
PE Ratio	x					150.5	122.5	37.0		
PEG	x					6.60	0.53	1.05		
Profitability										
Operating Margin	%		19.2	12.2	11.6	5.5	-5.2			+8.7%
ROA	%		43.4	14.8	9.5	2.6	0.8			
ROCE	%		43.7	26.3	31.0	3.7	-1.6			+20.6%
ROE	%		147.6	45.9	28.1	3.5	0.9			+45.2%
Cashflow										
Op. Cashflow ps	p	0.000	0.97	2.20	-1.37	-0.98	0.33			-23.9%
Capex ps	p	0.000	0.042	0.41	1.59	4.56	8.09			+273.1%
Free Cashflow ps	p	0.000	0.93	1.80	-2.96	-5.54	-7.76			
Dividends										
Dividend ps	p									
Dividend Growth	%									
Dividend Yield	%									
Dividend Cover	x									
Balance Sheet										
Cash etc	£m	0.000	1.29	3.07	2.07	11.7	25.3			+110.5%
Working Capital	£m	n/a	1.81	2.76	2.53	16.2	30.7			+103%
Net Fixed Assets	£m	0.000	0.19	0.18	0.14	0.19	0.54			+29.6%
Net Debt	£m	0.000	0.16	-0.98	1.67	-11.6	-25.1			
Book Value	£m	0.000	1.01	1.88	2.63	20.1	40.2			+151.1%
Average Shares	m	0.000	69.6	69.6	69.6	64.2	77.8			+2.8%
Book Value ps	p	0.000	1.45	2.70	3.78	28.9	47.9			+139.5%

Graphical History Current Fiscal Year 2021

Broker Forecasts				31st Dec 2021			31st Dec 2022		
Price Target: 2.00 (+79.41% above Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				800k	0.91	-	2.50m	3.01	-
1m Change				-	-0.050	-	-100.0k	-0.050	-
3m Change				-	-0.050	-	-100.0k	-0.050	-

Broker Consensus Trend

1 Broker ↗



Profile Summary



Diaceutics PLC is a United Kingdom-based data analytics and implementation services company which services the global pharmaceutical industry. The Company offers end to end services that encompasses from understanding the diagnostic landscape to test implementation into treatment pathways to enable better treatment decisions for patients.

The Company's data analytics and implementation services, including Landscape, Tracking, and Primary Market Research, leverages the diagnostic testing information to provide data-driven insights to drive seamless integration of diagnostic tests into treatment pathways. Its implementation services include Planning, Commercialization and Reimbursement Landscapes, to build the strategies and implement the tactics that drives optimal test utilization, ensuring that patients are getting the right treatment.

Directors:

No. of Employees: 120

No. of Shareholders: n/a

Last Annual	December 31st, 2020	Sector	Industrials
Last Interim	December 31st, 2020	Industry	Professional & Commercial Services
Incorporated	May 17, 2005	Index	FTSE Aim All Share ,
Public Since	March 21, 2019	Exchange	London Stock Exchange (AIM)
Shares in Issue	84,068,923	Eligible for	an ISA? a SIPP?
Free Float	43.3m (51.6%)		



Address Enterprise House 55-59 Adelaide Street, BELFAST, BT2 8FE, United Kingdom
Web <https://www.diaceutics.com/>
Phone +
Contact ()
Auditors PricewaterhouseCoopers LLP

DXRX Share Price Quote

DXRX Share Price Performance

DXRX Share Price	Day's Change	Volume	Bid - Ask	Low - High	Spread	1 year
GBp	-1.5 -1.3%	823	110.0 - 113.0	0.0 - 0.0	273bps	
110p		Avg Vol (3m)	Open - Close	12m Range	Beta	3 month
Traded 8:16am · Minimum 15 min delayed · NMS: 3.00k		75,517	111.5 - 111.5	98.0 - 152.0	0.00	

Latest DXRX News Announcements (delayed)

More »

- Tue 7:50am BRIEF-Diaceutics Posts H1 Pretax Loss
- Tue 7:00am Diaceutics PLC - Half-year Report
- 13th Sep BRIEF-Diaceutics Gets \$900,000 Contract With A Global Pharma Co
- 13th Sep Diaceutics PLC - DXRX Platform Contract Win
- 8th Sep RCS - Diaceutics PLC - Two new experts join the Diaceutics Advisory Panel

Upcoming DXRX Events

Wednesday 16th March, 2022 (Estimate)
 Full Year 2021 Diaceutics PLC Earnings Release

Recent ↓

Industry Peer Group

- Johnson Service**
Compare vs DXRX
- CMC Markets**
Compare vs DXRX
- Capita**
Compare vs DXRX
- Mitie**
Compare vs DXRX
- Serco**
Compare vs DXRX
- Learning Technolog...**
Compare vs DXRX
- Network Internatio...**
Compare vs DXRX
- Aggreko**
Compare vs DXRX

Industrials

Professional & Commercial Services

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2021.